Argos Therapeutics, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, revenue was $488,643 against $107,391 a year ago. Operating loss was $12,065,020 against $18,886,801 a year ago. Net loss was $12,606,245 against $19,604,818 a year ago. Net loss per share, basic and diluted was $0.48 against $0.95 a year ago. For the six months, revenue was $635,072 against $286,162 a year ago. Operating loss was $24,395,591 against $35,846,213 a year ago. Net loss was $25,426,433 against $37,151,033 a year ago. Net loss per share, basic and diluted was $1.04 against $1.84 a year ago.